MedTrace Logo

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

NCT05018013 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2021-11-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Ammoxetine hydrochloride enteric-coated tablets

Ammoxetine hydrochloride enteric-coated tablets

DRUG

Duloxetine hydrochloride enteric-coated capsules

Duloxetine hydrochloride enteric-coated capsules

DRUG

Placebo to Ammoxetine

Placebo to Ammoxetine

DRUG

Placebo to Duloxetine

Placebo to Duloxetine

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huang Yanli, MD · CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd

  • Li Huafang, Ph.D · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-21
Primary Completion
2022-08-01
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05018013 on ClinicalTrials.gov